While LS-1-2 also inhibited the growth of KRAS wild-type CRC cells, these cells exhibited reduced sensitivity (Difi IC50 = 0.9456 μM, HT29 IC50 = 1.379 μM, RKO IC50 = 3.049 μM, Caco-2 IC50 = 2.018 μM) compared to KRAS-mutant counterparts (Figure 2D). This evidence concerns the gene KRAS and colorectal carcinoma.